Related Experiment Videos
[Body plethysmographic investigations with the new bronchodilator NAB365 (author's transl)]
MMW, Munchener Medizinische Wochenschrift
|May 30, 1975
Abstract:
NAB 365, a new beta2-adrenergic bronchodilator was tested in oral doses of 0,01, 0,02, 0,03, and 0,04 mg. An acute trial was carried out in outpatients, suffering from chronic obstructive airways disease. with doses of 0,02 and 0,04 mg NAB 365 a quick, dose related and statistically significant bronchodilation without remarkable side effects was found.